Dogwood Therapeutics (DWTX) Competitors

$4.02

-0.41 (-9.26%)

(As of 11:50 AM ET)

DWTX vs. AYTU, CARA, TLPH, EDSA, APLM, SXTP, SNSE, VINC, JAGX, and EGRX

Should you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Aytu BioPharma (AYTU), Cara Therapeutics (CARA), Talphera (TLPH), Edesa Biotech (EDSA), Apollomics (APLM), 60 Degrees Pharmaceuticals (SXTP), Sensei Biotherapeutics (SNSE), Vincerx Pharma (VINC), Jaguar Health (JAGX), and Eagle Pharmaceuticals (EGRX). These companies are all part of the "pharmaceutical preparations" industry.

Dogwood Therapeutics vs.

Dogwood Therapeutics (NASDAQ:DWTX) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment, valuation and community ranking.

: Dogwood Therapeutics has higher earnings, but lower revenue than Aytu BioPharma. Aytu BioPharma is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dogwood Therapeutics N/A N/A -$5.30M -$6.00 -0.74
Aytu BioPharma $81.00M 0.17 -$15.84M -$2.63 -0.89
: Dogwood Therapeutics has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Aytu BioPharma has a beta of -1.43, indicating that its share price is 243% less volatile than the S&P 500.
: Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dogwood Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
Aytu BioPharma
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
N/A
: Dogwood Therapeutics has a net margin of 0.00% compared to Aytu BioPharma's net margin of -19.56%. Aytu BioPharma's return on equity of -51.31% beat Dogwood Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Dogwood Therapeutics N/A -130.33% -115.00%
Aytu BioPharma -19.56% -51.31% -12.40%
: 9.1% of Dogwood Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 12.2% of Dogwood Therapeutics shares are owned by insiders. Comparatively, 2.8% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: In the previous week, Dogwood Therapeutics and Dogwood Therapeutics both had 2 articles in the media. Aytu BioPharma's average media sentiment score of 1.19 beat Dogwood Therapeutics' score of 1.00 indicating that Aytu BioPharma is being referred to more favorably in the news media.
Company Overall Sentiment
Dogwood Therapeutics Positive
Aytu BioPharma Positive
: Aytu BioPharma received 255 more outperform votes than Dogwood Therapeutics when rated by MarketBeat users.
Company Underperform Outperform
Dogwood Therapeutics N/A N/A
Aytu BioPharma Outperform Votes
255
67.11%
Underperform Votes
125
32.89%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dogwood Therapeutics	N/A	N/A	-$5.30M	-$6.00	-0.74
Aytu BioPharma	$81.00M	0.17	-$15.84M	-$2.63	-0.89

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dogwood Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Aytu BioPharma	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Company	Net Margins	Return on Equity	Return on Assets
Dogwood Therapeutics	N/A	-130.33%	-115.00%
Aytu BioPharma	-19.56%	-51.31%	-12.40%

Company	Overall Sentiment
Dogwood Therapeutics	Positive
Aytu BioPharma	Positive

Company	Underperform	Outperform
Dogwood Therapeutics	N/A	N/A
Aytu BioPharma	Outperform Votes 255 67.11%	Underperform Votes 125 32.89%

Summary

Aytu BioPharma beats Dogwood Therapeutics on 7 of the 12 factors compared between the two stocks.

Ad Weiss Ratings

Crypto’s next big bull run?

Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on November 5. Just a day after the American election, Juan believes crypto could start a massive run up …

And one special coin could do even better.

Get Dogwood Therapeutics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DWTX vs. The Competition

Export to Excel

Metric	Dogwood Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.96M	$6.11B	$5.55B	$8.47B
Dividend Yield	N/A	9.33%	4.72%	4.12%
P/E Ratio	-0.74	19.82	116.52	20.22
Price / Sales	N/A	265.92	1,191.87	70.71
Price / Cash	N/A	48.13	39.25	33.54
Price / Book	0.90	5.81	4.93	4.69
Net Income	-$5.30M	$125.24M	$120.67M	$227.38M
7 Day Performance	N/A	6.97%	7.10%	4.78%
1 Month Performance	N/A	21.50%	18.98%	14.24%
1 Year Performance	N/A	28.18%	32.28%	26.46%

Dogwood Therapeutics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DWTX Dogwood Therapeutics	N/A	$4.02 -9.3%	N/A	N/A	$4.50M	N/A	-0.67	4	Analyst Revision Positive News Gap Down High Trading Volume
AYTU Aytu BioPharma	1.3589 of 5 stars	$2.24 flat	N/A	-23.6%	$13.78M	$81M	-0.78	160	Short Interest ↓ Gap Up
CARA Cara Therapeutics	4.5287 of 5 stars	$0.25 flat	$2.32 +825.8%	-82.5%	$13.70M	$11.00M	-0.12	80	Gap Up
TLPH Talphera	2.5481 of 5 stars	$0.79 -1.3%	$4.50 +469.6%	N/A	$13.42M	$398,000.00	-1.23	19	Positive News Gap Up
EDSA Edesa Biotech	3.6577 of 5 stars	$4.05 -0.7%	$39.00 +863.5%	-3.8%	$13.16M	N/A	0.00	20	Positive News Gap Up
APLM Apollomics	3.0638 of 5 stars	$0.14 +7.7%	$2.00 +1,328.6%	-93.8%	$12.53M	$1.22M	0.00	45	Positive News
SXTP 60 Degrees Pharmaceuticals	3.2485 of 5 stars	$1.02 -2.9%	N/A	+53.8%	$12.45M	$418,304.00	11.12	3	Positive News
SNSE Sensei Biotherapeutics	4.3435 of 5 stars	$0.47 flat	$4.33 +822.0%	-38.9%	$11.79M	N/A	-0.40	40	News Coverage Positive News Gap Up
VINC Vincerx Pharma	3.9817 of 5 stars	$0.39 flat	$2.00 +410.2%	-61.4%	$11.63M	N/A	-0.30	60	Gap Up
JAGX Jaguar Health	0.1939 of 5 stars	$1.25 -0.8%	N/A	-94.3%	$11.55M	$9.76M	0.00	50	Short Interest ↑
EGRX Eagle Pharmaceuticals	3.1129 of 5 stars	$0.88 +47.1%	N/A	-94.1%	$11.37M	$316.61M	0.00	100	Short Interest ↑ Gap Up